Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001934553 | SCV002134267 | pathogenic | Nephronophthisis 15 | 2021-12-13 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant has not been reported in the literature in individuals affected with CEP164-related conditions. This variant is present in population databases (rs774951398, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Arg837*) in the CEP164 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CEP164 are known to be pathogenic (PMID: 22863007, 28125082, 32367404, 34132027, 34499853). |
Fulgent Genetics, |
RCV001934553 | SCV002801696 | likely pathogenic | Nephronophthisis 15 | 2022-03-03 | criteria provided, single submitter | clinical testing |